跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,786 条关于
“H3 K27M-mutant diffuse midline glioma”
全部
6,786
临床试验
5,081
药物
213
机构
28
资讯
1,464
去年
FDA Approves Modeyso as First Treatment for Recurrent H3 K27M-Mutant Diffuse Midline Glioma
去年
Dordaviprone Shows Promise in Recurrent H3 K27M-Mutant Glioma: Updated Phase 2 Data
4个月前
HealthCare Royalty Secures Modeyso Royalty Rights Following Strong Early Commercial Performance
去年
Chimerix's Dordaviprone Shows Promising Response in Recurrent Glioma Phase 2 Trial
去年
FDA Grants First Accelerated Approval for H3 K27M-Mutated Diffuse Midline Glioma with Dordaviprone
7个月前
Artios Pharma Strengthens Leadership Team with Three Key Appointments to Advance DNA Damage Response Pipeline
14天前
FDA Grants First-Ever Approval for DIPG Treatment as Family Advocacy Fuels Research Momentum
8个月前
Jazz Pharmaceuticals Reports Record $4.3 Billion Revenue in 2025, Prepares Zanidatamab Launch for Gastroesophageal Cancer
去年
FDA Grants Priority Review to Dordaviprone for Recurrent H3 K27M-Mutant Diffuse Glioma
去年
Chimerix Seeks Accelerated FDA Approval for Dordaviprone in H3 K27M-Mutant Glioma
第 1 页，共 147 页
上一页
下一页
